Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension

ID
Name
AD-223P3
Description
The purpose of this study is to evaluate the efficacy and safety of AD-223
Trial arms
Trial start
2024-03-01
Estimated PCD
2025-02-01
Trial end
2025-02-01
Status
Recruiting
Phase
Early phase I
Treatment
AD-223A
PO, Once daily(QD), 8weeks
Arms:
Control group 1, Test group
AD-223B
PO, Once daily(QD), 8weeks
Arms:
Control group 2, Test group
AD-223C
PO, Once daily(QD), 8weeks
Arms:
Control group 3
AD-223A Placebo
PO, Once daily(QD), 8weeks
Arms:
Control group 2, Control group 3
AD-223B Placebo
PO, Once daily(QD), 8weeks
Arms:
Control group 1, Control group 3
AD-223C Placebo
PO, Once daily(QD), 8weeks
Arms:
Control group 1, Control group 2, Test group
Size
486
Primary endpoint
Change rate of MSSBP
Baseline, Week 8
Eligibility criteria
Inclusion Criteria: * Signed informed consent * Other inclusions applied Exclusion Criteria: * Orthostatic hypotension with symptom * Other exclusions applied
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 486, 'type': 'ESTIMATED'}}
Updated at
2024-01-31

1 organization

3 products

1 indication

Organization
Addpharma
Product
AD-223A
Indication
Hypertension,Essential
Product
AD-223C
Product
AD-223B